ALT · Insider Trading
Altimmune, Inc. Common Stock
Every open-market purchase and sale reported by ALT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Christophe Arbet-Engels | Chief Medical Officer | MIXED | +24,821 | −$34.99K |
| 2026-10-05 | Gregory L Weaver | Chief Financial Officer | MIXED | +10,096 | −$12.09K |
| 2026-10-02 | Richard Thomas Menziuso | Principal Accounting Officer | A | +120,780 deriv. | — |
| 2026-09-17 | Linda M Richardson | Chief Commercial Officer | MIXED | +17,174 | −$22.12K |
| 2026-08-13 | Jerome Benedict Durso | President and CEO | Buy | +15,000 | +$44.25K |
| 2026-08-03 | Gregory L Weaver | Chief Financial Officer | A | +1,753 | +$4.23K |
| 2026-08-03 | M Scot Roberts | Chief Scientific Officer | A | +875 | +$2.11K |
| 2026-05-01 | Philip Hodges | Director | A | +48,800 deriv. | — |
| 2026-05-01 | Mitchel Sayare | Director | A | +48,800 deriv. | — |
| 2026-05-01 | Diane Jorkasky | Director | A | +48,800 deriv. | — |
| 2026-05-01 | Klaus Schafer | Director | A | +48,800 deriv. | — |
| 2026-05-01 | Catherine A. Sohn | Director | A | +48,800 deriv. | — |
| 2026-05-01 | Teri L Lawver | Director | A | +48,800 deriv. | — |
| 2026-05-01 | Wayne Pisano | Director | A | +48,800 deriv. | — |
| 2026-05-01 | John Gill | Director | A | +48,800 deriv. | — |
| 2026-04-06 | John Gill | Director | Buy | +9,200 | +$31.35K |
| 2026-04-01 | Gregory L Weaver | Chief Financial Officer | Buy | +10,000 | +$31.50K |
| 2026-04-01 | Jerome Benedict Durso | President and CEO | Buy | +15,000 | +$47.10K |
| 2026-03-09 | Gregory L Weaver | Chief Financial Officer | Buy | +5,000 | +$17.70K |
| 2026-03-09 | Jerome Benedict Durso | President and CEO | Buy | +20,000 | +$70.79K |
| 2026-02-27 | M Scot Roberts | Chief Scientific Officer | A | +318,100 deriv. | — |
| 2026-02-27 | Gregory L Weaver | Chief Financial Officer | A | +370,000 deriv. | — |
| 2026-02-03 | M Scot Roberts | Chief Scientific Officer | MIXED | +17,429 | −$11.85K |
| 2026-02-02 | Raymond M Jordt | Chief Business Officer | A | +4,571 | +$14.03K |
| 2026-02-02 | Vipin K Garg | Director | MIXED | +22,069 | −$43.88K |
| 2026-01-29 | Raymond M Jordt | Chief Business Officer | MIXED | +11,621 | −$26.14K |
| 2026-01-29 | M Scot Roberts | Chief Scientific Officer | MIXED | +11,102 | −$29.34K |
| 2026-01-29 | Vipin K Garg | Director | MIXED | +23,302 | −$110.61K |
| 2026-01-27 | M Scot Roberts | Chief Scientific Officer | MIXED | +10,227 | −$24.05K |
| 2026-01-27 | Raymond M Jordt | Chief Business Officer | MIXED | +10,745 | −$21.20K |
| 2026-01-27 | Vipin K Garg | Director | MIXED | +24,066 | −$98.91K |
| 2026-01-09 | Wayne Pisano | Director | Buy | +5,000 | +$20.41K |
| 2026-01-05 | Catherine A. Sohn | Director | Buy | +500 | +$2.12K |
| 2026-01-05 | Raymond M Jordt | Chief Business Officer | MIXED | +6,900 | −$8.93K |
| 2025-12-29 | Diane Jorkasky | Director | Buy | +527 | +$2.00K |
| 2025-12-23 | John Gill | Director | Buy | +12,500 | +$51.25K |
| 2025-12-22 | Jerome Benedict Durso | Director | Buy | +12,500 | +$51.57K |
| 2025-12-01 | Jerome Benedict Durso | CEO-elect | A | +2,458,100 deriv. | — |
| 2025-11-12 | Gregory L Weaver | Chief Financial Officer | MIXED | +13,078 | −$24.28K |
| 2025-10-03 | Gregory L Weaver | Chief Financial Officer | A | +224,700 deriv. | — |
| 2025-10-03 | Christophe Arbet-Engels | Chief Medical Officer | A | +600,000 deriv. | — |
| 2025-09-29 | Diane Jorkasky | Director | A | +48,800 deriv. | — |
| 2025-09-29 | Klaus Schafer | Director | A | +48,800 deriv. | — |
| 2025-09-29 | Teri L Lawver | Director | A | +48,800 deriv. | — |
| 2025-09-29 | Wayne Pisano | Director | A | +48,800 deriv. | — |
| 2025-09-29 | Philip Hodges | Director | A | +48,800 deriv. | — |
| 2025-09-29 | Catherine A. Sohn | Director | A | +48,800 deriv. | — |
| 2025-09-29 | Jerome Benedict Durso | Director | A | +48,800 deriv. | — |
| 2025-09-29 | John Gill | Director | G | −2,714 | — |
| 2025-09-29 | Mitchel Sayare | Director | A | +48,800 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Vipin K Garg | President and CEO | 429,225 | $957.17K |
| M Scot Roberts | Chief Scientific Officer | 113,714 | $253.58K |
| Matthew Scott Harris | Chief Medical Officer | 83,874 | $187.04K |
| Raymond M Jordt | Chief Business Officer | 70,107 | $156.34K |
| Jerome Benedict Durso | President and CEO | 62,500 | $139.38K |
| Gregory L Weaver | Chief Financial Officer | 49,927 | $111.34K |
| Christophe Arbet-Engels | Chief Medical Officer | 37,500 | $83.62K |
| Mitchel Sayare | Director | 27,451 | $61.22K |
| Philip Hodges | Director | 26,579 | $59.27K |
| John Gill | Director | 21,700 | $48.39K |
| Linda M Richardson | Chief Commercial Officer | 17,174 | $38.30K |
| Wayne Pisano | Director | 13,498 | $30.10K |
| Klaus Schafer | Director | 9,179 | $20.47K |
| Catherine A. Sohn | Director | 1,500 | $3.35K |
| Diane Jorkasky | Director | 527 | $1.18K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ALT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.